natgillin/translations-raw huggingface dataset:
Patients with a myocardial infarction during the previous 6 months, unstable angina, newly diagnosed arrhythmia within the previous 3 months, QTc (Bazett's method) above 470 msec, or hospitalisation within the previous 12 months for heart failure functional classes III and IV as per the “New York Heart Association” were excluded from the clinical studies, therefore Brimica Genuair should be used with caution in these patients groups. 
Brimica Genuair treba koristiti oprezno kod bolesnika s infarktom miokarda u prethodnih 6 mjeseci, nestabilnom anginom, novodijagnosticiranom aritmijom u prethodna 3 mjeseca, QTc-om (Bazzettova formula) iznad 470 msek ili hospitalizacijom u prethodnih 12 mjeseci zbog zatajenja srca klase III i IV, prema „New York Heart Association“ (NYHA) klasifikaciji.
Effects of aclidinium in nonclinical studies with respect to reproductive toxicity (foetotoxic effects) and fertility (slight decreases in conception rate, number of corpora lutea, and pre- and post implantation losses) were observed only at exposures considered sufficiently in excess of themaximum human exposure indication to be of little relevance to clinical use. 
U nekliničkim ispitivanjima zapaženi su učinci aklidinija s obzirom na reproduktivnu toksičnost (fetotoksični učinci) i plodnost (blago smanjenje stope začeća, broja žutih tijela, te pred- i postimplantacijskih gubitaka) samo pri izloženostima koje su bile znatno veće od maksimalnih izloženosti u ljudi, što ukazuje na njihov mali značaj za kliničku primjenu.
Elderly No dose adjustments are required in elderly patients (see section 5.2). 
Nije potrebno prilagođavati dozu za starije bolesnike (vidjeti dio 5.2).
The number of steps/day in the Brimica Genuair treatment group was maintained resulting in a treatment effect compared to placebo of 510 steps/day (p=0.1588) and a reduction versus placebo in the percentage of inactive patients (<6000 steps per day) (41.5% compared to 50.4%; p=0.1134). 
Broj koraka po danu u skupini liječenoj lijekom Brimica Genuair održan je rezultirajući učinkom liječenja u usporedbi sa placebom od 510 koraka po danu (p=0,1588) i u smanjenju postotka neaktivnih bolesnika (<6000 koraka po danu) u usporedbi sa placebom (41,5% u usporedbi sa 50,4%; p=0.1134).
The Genuair inhaler is a white device fitted with an integral dose indicator and an orange dosage button. 
Genuair inhalator je bijela naprava s ugrađenim pokazivačem doze i narančastim gumbom za doziranje.
Do not hold the orange button down while inhaling. 
Nemojte pritiskati narančasti gumb dok inhalirate lijek.
Since no dosage adjustments are needed for either aclidinium or formoterol medicinal products in patients with renal or hepatic impairment, no dosage adjustment is warranted for aclidinium/formoterol. 
S obzirom da za bolesnike s oštećenjem jetre ili bubrega nisu potrebne prilagodbe doze ni aklidinija ni formoterola, nije potrebna ni prilagodba doze aklidinija/formoterola.
The pooled analysis of these two studies showed Brimica Genuair to be associated with statistically significantly greater improvements in TDI focal score compared to aclidinium (0.4 units, p=0.016) or formoterol (0.5 units, p=0.009). 
Združena analiza ovih dvaju ispitivanja pokazala je da je Brimica Genuair povezan sa statistički značajno većim poboljšanjem u ukupnom rezultatu TDI u usporedbi s aklidinijem (0,4 jedinice, p=0,016) ili formoterolom (0,5 jedinica, p=0,009).
Uncommon (may affect up to 1 in 100 people) - Muscle weakness, twitching and/or abnormal heart rhythm, as these may be signs of a decrease in the amount of potassium in your blood - Tiredness, increased thirst and/or a need to pass urine more frequently than usual, as these may be signs of an increase in the amount of sugar in your blood - Palpitations, as these may be a sign of an unusually fast heart beat or an abnormal heart rhythm 
Manje često (mogu se javiti u do 1 na 100 osoba) - Slabost u mišićima, trzanje mišića i/ili abnormalni srčani ritam, jer bi to mogli biti znakovi smanjenja količine kalija u krvi - Umor, povećana žeđ i/ili češća potreba za mokrenjem nego što je uobičajeno, jer bi to mogli biti znakovi povećane količine šećera u krvi.
What Brimica Genuair is 
Što je Brimica Genuair
Since no dosage adjustments are needed for either aclidinium or formoterol medicinal products in elderly patients, no dosage adjustment is warranted for aclidinium/formoterol in geriatric patients. 
S obzirom da za starije bolesnike nisu potrebne prilagodbe doze ni aklidinija ni formoterola, nije potrebna ni prilagodba doze aklidinija/formoterola.
Dysphonia Throat irritation 
Disfonija Iritacija grla
The percentage of patients in AUGMENT who achieved a clinically meaningful improvement from baseline in SGRQ total score (defined as a decrease of at least 4 units) was higher with Brimica Genuair than with placebo (58.2% compared to 38.7%, respectively; p<0.001). 
Postotak bolesnika u ispitivanju AUGMENT koji su postigli klinički značajno poboljšanje od početne vrijednosti u SGRQ ukupnom rezultatu (definirano kao smanjenje od najmanje 4 jedinice) bio je veći s Brimica Genuairom nego s placebom (58,2% u usporedbi s 38,7%; p<0,001).
This corresponds to a metered dose of 400 micrograms of aclidinium bromide (equivalent to 343 micrograms of aclidinium) and a metered dose of 12 micrograms of formoterol fumarate dihydrate. 
To odgovara odmjernoj dozi od 400 mikrograma aklidinijeva bromida (što odgovara 343 mikrograma aklidinija) i odmjernoj dozi od 12 mikrograma formoterolfumarat dihidrata.
Efficacy was assessed by measures of lung function, symptomatic outcomes, disease-specific health status, rescue medication use, and exacerbations. 
Djelotvornost je procijenjena mjerenjem funkcije pluća, prema simptomatskim ishodima, zdravstvenom stanju specifičnom za bolest, uzimanju lijeka za hitno ublažavanje simptoma i pojavi egzacerbacija.
The percentages of patients with clinically meaningful improvements in TDI focal score (defined as an increase of at least 1 unit) were higher with Brimica Genuair than with placebo in ACLIFORM-COPD (64.8% compared to 45.5%; p<0.001) and AUGMENT (58.1% compared to 36.6%; p<0.0001). 
Postotci bolesnika sa klinički značajnim poboljšanjem u ukupnom rezultatu TDI (definirano kao porast od najmanje 1 jedinice) bili su veći s Brimica Genuairom nego s placebom u ispitivanju AKLIFORMCOPD (64,8% u usporedbi s 45,5%; p<0,0001) i u ispitivanju AUGMENT (58,1% u usporedbi s 36,6%; p<0,0001).
There is limited evidence on the management of overdose with Brimica Genuair. 
Podaci o zbrinjavanju predoziranja Brimica Genuairom su ograničeni.
Brimica Genuair provided a clinically meaningful improvement in breathlessness (assessed by the Transition Dyspnoea Index [TDI]) with an improvement in the TDI focal score at 6 months compared to placebo of 1.29 units in study ACLIFORM-COPD (p<0.0001) and 1.44 units in study AUGMENT (p<0.0001). 
Transition Dyspnoea Index, TDI]) uz poboljšanje u ukupnom rezultatu TDI nakon 6 mjeseci u usporedbi s placebom od 1,29 jedinica u ispitivanju ACLIFORM-COPD (p<0,0001), odnosno od 1,44 jedinice u ispitivanju AUGMENT (p<0,0001).
How to store Brimica Genuair 
Kako primjenjivati Brimica Genuair
No clinically significant effects of Brimica Genuair on cardiac rhythm were observed on 24-hour Holter monitoring in a subset of 551 patients, of whom 114 received Brimica Genuair twice daily. 
24-satnim Holter praćenjem podskupine od 551 bolesnika, od kojih je 114 primalo Brimica Genuair dvaput dnevno, nisu zabilježeni klinički značajni učinci lijeka Brimica Genuair na srčani ritam.
In addition, a higher percentage of patients receiving Brimica Genuair responded with a clinically meaningful improvement in TDI focal score compared to either aclidinium or formoterol (61.9% compared to 55.7% and 57.0%, respectively; p=0.056 and p=0.100, respectively). 
Uz to, veći postotak bolesnika koji su primali Brimica Genuair odgovorio je klinički značajnim poboljšanjem u ukupnom rezultatu TDI u usporedbi s aklidinijem ili formoterolom (61,9% u usporedbi s 55,7% i 57,0%; p=0,056 i p=0,100).
In addition, a higher percentage of patients receiving Brimica Genuair responded with a clinically meaningful improvement in SGRQ total score compared to aclidinium and formoterol (56.6% compared to 53.9% and 52.2%, respectively; p=0.603 and p=0.270, respectively). 
Uz to, veći postotak bolesnika koji su primali Brimica Genuair odgovorio je klinički značajnim poboljšanjem u SGRQ ukupnom rezultatu u usporedbi s aklidinijem ili formoterolom (56,6% u usporedbi s 53,9% i 52,2%; p=0,603 i p=0,270).
In study ACLIFORM-COPD, Brimica Genuair showed improvements in FEV1 at 1 hour post-dose relative to placebo and aclidinium of 299 ml and 125 ml, respectively (both p<0.0001) and improvements in trough FEV1 relative to placebo and formoterol of 143 ml and 85 ml, respectively (both p<0.0001). 
U ispitivanju ACLIFORM-COPD, Brimica Genuair je pokazao poboljšanja u FEV1 jedan sat nakon doze u odnosu na placebo od 299 ml, i u odnosu na aklidinij od 125 ml (oba p < 0,0001), te poboljšanja najnižeg FEV1 u odnosu na placebo od 143 ml, i u odnosu na formoterol od 85 ml (oba p < 0,0001).
c. Pull off the cap by lightly squeezing the arrows marked on each side (Figure B). 
c) Da biste skinuli kapicu, lagano pritisnite strelice na njezinim bočnim stranama i povucite kapicu (Slika B).
Brimica Genuair 340 micrograms /12 micrograms inhalation powder 
Brimica Genuair 340 mikrograma/12 mikrograma, prašak inhalata
Brimica Genuair reduced the use of rescue medication over 6 months compared to placebo (by 0.9 puffs per day [p<0.0001]), aclidinium (by 0.4 puffs/day [p<0.001]) and formoterol (by 0.2 puffs/day [p=0.062]). 
Uporaba lijekova za hitno ublažavanje simptoma Brimica Genuair je smanjio uporabu lijekova za hitno ublažavanje simptoma tijekom 6 mjeseci u usporedbi s placebom (za 0,9 udisaja dnevno [p < 0,0001]), aklidinijem (za 0,4 udisaja dnevno [p < 0,001]) i formoterolom (za 0,2 udisaja dnevno [p=0,062]).
In study AUGMENT, Brimica Genuair showed improvements in FEV1 at 1 hour post-dose relative to placebo and aclidinium of 284 ml and 108 ml (both p<0.0001), respectively, and improvements in trough FEV1 relative to placebo and formoterol of 130 ml (p<0.0001) and 45 ml (p=0.01), respectively. 
U ispitivanju AUGMENT, Brimica Genuair je pokazao poboljšanja u FEV1 jedan sat nakon doze u odnosu na placebo od 284 ml, i u odnosu na aklidinij od 108 ml (oba p < 0,0001), te poboljšanja najnižeg FEV1 u odnosu na placebo od 130 ml (p < 0,0001) i u odnosu na formoterol od 45 ml (p=0,01).
Brimica Genuair is unlikely to affect your ability to drive or use machines. 
Malo je vjerojatno da će Brimica Genuair utjecati na sposobnost upravljanja vozilom i rada sa strojevima.
Before first use, the sealed bag should be teared open, and the inhaler removed. 
Prije prve uporabe, potrebno je otvoriti zatvorenu vrećicu i izvaditi inhalator.
It is white-coloured with an integral dose indicator and an orange dosage button. 
Bijele je boje s ugrađenim pokazivačem doze i narančastim gumbom za doziranje.
Common (may affect up to 1 in 10 people) - Combination of sore throat and runny nose - these may be signs of nasopharyngitis - Headache - Painful and/or frequent urination - these may be signs of a urinary tract infection - Cough - Diarrhoea - A blocked, runny or stuffy nose and/or pain or a feeling of pressure in the cheeks or forehead these may be symptoms of sinusitis - Dizziness - Muscle cramps - Nausea (feeling sick) - Difficulty sleeping - Dry mouth - Muscle pain - Abscess (infection) in the tissues at the base of a tooth - Increased blood levels of a protein found in muscle called creatine phosphokinase - Shaking/tremor - Anxiety 
Često (mogu se javiti u do 1 na 10 osoba) - Kombinacija upaljenog grla i curenja nosa - mogu biti znakovi nazofaringitisa - Glavobolja - Bolno i/ili često mokrenje - mogu biti znakovi infekcije mokraćnog sustava - Kašalj - Proljev - Začepljen, pun nos ili nos koji curi i/ili bol ili osjećaj pritiska u obrazima ili čelu - mogu biti simptomi sinusitisa.
No dose adjustments are required in patients with hepatic impairment (see section 5.2). 
Nije potrebno prilagođavati dozu za bolesnike s oštećenjem bubrega (vidjeti dio 5.2).
Metabolic effects of hyperglycaemia and hypokalaemia may be observed with high doses of β2-adrenergic agonists. 
Pri visokim dozama β2-adrenergičkih agonista mogu se primijetiti metabolički učinci hiperglikemije i hipokalemije.
Carton containing 3 inhalers each with 60 doses. 
Kutija sadrži 3 inhalatora, svaki sa 60 doza.
Respiratory, Thoracic and mediastinal disorders 
Poremećaji dišnog sustava, prsišta i sredoprsja
a.Before first use, tear open the sealed bag and remove the inhaler. 
a) Prije prve uporabe otvorite zatvorenu vrećicu i izvadite inhalator.
INHALER LABEL 
NALJEPNICA NA INHALATORU
Brimica Genuair 340 mcg/12 mcg inhalation powder aclidinium/formoterol fumarate dihydrate 
Brimica Genuair 340/12 μg, prašak inhalata aklidinij/formoterolfumarat dihidrat
Inhaled aclidinium bromide acts locally in the lungs to antagonise M3 receptors of airway smooth muscle and induce bronchodilation. 
M3 receptora glatkih mišića dišnih putova i izaziva bronhodilataciju.
What Brimica Genuair is used for 
Za što se koristi Brimica Genuair
The low absolute bioavailability of inhaled aclidinium (<5%) is because aclidinium undergoes extensive systemic and pre-systemic hydrolysis whether deposited in the lung or swallowed. 
Bilo da se nakupi u plućima ili proguta, aklidinij prolazi opsežnu sistemsku i predsistemsku hidrolizu što za posljedicu ima nisku apsolutnu bioraspoloživost inhaliranog aklidinija (<5%).
Each delivered dose contains 396 micrograms aclidinium bromide (equivalent to 340 micrograms of aclidinium) and 11.8 micrograms of formoterol fumarate dihydrate. 
Jedna isporučena doza sadrži 396 mikrograma aklidinijeva bromida (što odgovara 340 mikrograma aklidinija) i 11,8 mikrograma formoterolfumarat dihidrata.
Each delivered dose (the dose leaving the mouthpiece) contains 396 micrograms aclidinium bromide equivalent to 340 micrograms of aclidinium and 11.8 micrograms of formoterol fumarate dihydrate. 
Jedna isporučena doza (doza koja se isporuči iz inhalatora) sadrži 396 mikrograma aklidinijeva bromida što odgovara 340 mikrograma aklidinija i 11,8 mikrograma formoterolfumarat dihidrata.
Each delivered dose (the dose leaving the mouthpiece) contains 396 micrograms of aclidinium bromide (equivalent to 340 micrograms of aclidinium) and 11.8 micrograms of formoterol fumarate dihydrate. 
Jedna isporučena doza (doza oslobođena iz nastavka za usta) sadrži 396 mikrograma aklidinijeva bromida (što odgovara 340 mikrograma aklidinija) i 11,8 mikrograma formoterolfumarat dihidrata.
Taking your medicine at regular times will also help you to remember to use it. - The recommended dose can be used for elderly patients and for patients with kidney or liver problems. 
- Preporučenu dozu mogu koristiti i stariji bolesnici te bolesnici s oštećenjem bubrega ili jetre.
- If you have thyroid gland problems (thyrotoxicosis). 
- ako imate tegobe sa štitnjačom (tireotoksikoza).
COPD exacerbation reductions 
Smanjenje egzacerbacija KOPB-a
Brimica Genuair 340 micrograms /12 micrograms inhalation powder aclidinium/formoterol fumarate dihydrate 
Brimica Genuair 340/12 mikrograma, prašak inhalata aklidinij/formoterolfumarat dihidrat
Mouthpiece 
Kašalj
Brimica Genuair 340 micrograms/12 micrograms inhalation powder aclidinium/formoterol fumarate dihydrate 
Brimica Genuair 340 mikrograma/12 mikrograma, prašak inhalata aklidinij/formoterolfumarat dihidrat
Brimica Genuair should be discontinued in case of overdose. 
U slučaju predoziranja, primjenu Brimica Genuaira treba prekinuti.
Renal and urinary disorders Urinary retention 
Retencija urina
Myalgia Muscle spasms 
Mialgija Mišićni spazam
Tooth abscess 
Apsces zuba
Renally and hepatically impaired patients 
Bolesnici s oštećenjem bubrega i jetre
Date of first authorisation: 8 December 2017 
Datum prvog odobrenja: 8. prosinca 2017.
This medicine should be taken once a day. 
Ovaj se lijek treba uzeti jedanput na dan.
Tacforius with food and drink 
Tacforius s hranom i pićem
If you have forgotten to take your capsules in the morning, take them as soon as possible on the same day. 
Ako ste ujutro zaboravili uzeti kapsule, uzmite ih čim prije istog dana.
Other interactions leading to clinically detrimental effects 
Druge interakcije koje dovode do klinički štetnih učinaka
After opening the aluminium wrapper: 1 year 
Nakon otvaranja aluminijskog omota: 1 godina
The course of preexisting infections may be aggravated. 
Tijek postojećih infekcija može se pogoršati.
Limited data are available but no recommendation on a posology can be made. 
Dostupni su ograničeni podaci međutim nije moguće dati preporuku o doziranju.
Other medicines and Tacforius 
Drugi lijekovi i Tacforius
If you are pregnant or breast-feeding, think you might be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. 
Ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku za savjet prije nego uzmete ovaj lijek.
What Tacforius is and what it is used for 
Što je Tacforius i za što se koristi
Elderly There is no evidence currently available to indicate that dosing should be adjusted in the elderly. 
Starije osobe Trenutno nema dostupnih dokaza koji pokazuju da se u starijih osoba mora prilagoditi doza.
If you take more Tacforius than you should 
Ako uzmete više Tacforiusa nego što ste trebali
Tacforius is used in adults. 
Tacforius se primjenjuje u odraslih.
Contents of the pack and other information What Tacforius contains 
Sadržaj pakiranja i druge informacije Što Tacforius sadrži
If you have accidentally taken too many capsules, contact your doctor or nearest hospital emergency department immediately. 
Ako ste slučajno uzeli previše kapsula, odmah se javite liječniku ili otiđite u najbližu službu hitne pomoći.
Tacforius is not recommended for use in children below 18 years due to limited data on safety and/or efficacy. 
Ne preporučuje se primjena Tacforiusa u djece mlađe od 18 godina, zbog ograničenih podataka o sigurnosti i/ili djelotvornosti.
Following your organ transplant (liver, kidney), your body's immune system will try to reject the new organ. 
Nakon presađivanja organa (jetre, bubrega), Vaš imunološki sustav pokušat će odbaciti novi organ.
Therefore, you may be more prone to infections while you are taking Tacforius. 
Zbog toga možete postati osjetljiviji na infekcije dok uzimate Tacforius.
- if you are allergic to tacrolimus or any of the other ingredients of this medicine (listed in section 6). 
- ako ste alergični na takrolimus ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
98.8%) to plasma proteins, mainly to serum albumin and α - 1-acid glycoprotein. 
(> 98,8%) za proteine plazme, uglavnom za serumski albumin i α-1-kiseli glikoprotein.
What Tacforius looks like and contents of the pack 
Kako Tacforius izgleda i sadržaj pakiranja
Tubing, syringes and other equipment used to prepare a suspension of Tacforius capsule contents must not contain PVC. 
Cijevi, štrcaljke i ostali pribor koji se koristi u pripremi suspenzije sadržaja kapsule Tacforiusa ne smije sadržavati PVC.
Your doctor will usually reduce your Tacforius dose once your condition has stabilised. 
Liječnik će obično smanjiti dozu Tacforiusa kad Vam se stanje stabilizira.
The safety and efficacy of Tacforius in children under 18 years of age have not yet been established. 
Sigurnost i djelotvornost Tacforiusa u djece mlađe od 18 godina nisu još ustanovljene.
You will need to take Tacforius every day as long as you need immunosuppression to prevent rejection of your transplanted organ. 
Tacforius ćete morati uzimati svakodnevno, sve dok Vam je potrebna imunosupresija, da bi se spriječilo odbacivanje presađenog organa.
As detrimental effects on the newborn cannot be excluded, women should not breast-feed whilst receiving Tacforius. 
Budući da se ne mogu isključiti štetni učinci na novorođenče, žene ne bi smjele dojiti dok uzimaju Tacforius.
Administration should commence approximately 12 - 18 hours after the completion of surgery. 
S primjenom treba započeti oko 12-18 sati nakon završetka operacije.
fever, nausea or vomiting - if you have an alteration of the electrical activity of your heart called “QT prolongation”. 
mučnina ili povraćanje - ako imate promjenu električne aktivnosti srca zvane „produljenje QT-a“.
It is not recommended that Tacforius is taken with ciclosporin (another medicine used for the prevention of transplant organ rejection). 
Ne preporučuje se uzimanje Tacforiusa zajedno s ciklosporinom (drugi lijek koji se koristi za sprječavanje odbacivanja organa nakon presađivanja).
Positive EBV-PCR may persist for months and is per se not indicative of lymphoproliferative disease or lymphoma. 
Pozitivan nalaz PCR-a na EBV može trajati mjesecima i nije sam po sebi indikativan za limfoproliferativnu bolest ili limfom.
Not known (frequency cannot be estimated from the available data) - Abnormality of the optic nerve (optic neuropathy) 
Nepoznato (učestalost se ne može procijeniti iz dostupnih podataka): - poremećaj vidnog živca (optička neuropatija)
As gastrointestinal perforation is a medically important event that may lead to a life-threatening or serious condition, adequate treatments should be considered immediately after suspected symptoms or signs occur. 
S obzirom na to da je gastrointestinalna perforacija medicinski važan događaj koji može dovesti do ozbiljnog stanja ili stanja opasnog po život, trebalo bi provesti adekvatno liječenje odmah nakon sumnje na simptome ili znakove koji se pojave.
Your doctor may need to adjust your dose of Tacforius. 
Liječnik će Vam možda morati prilagoditi dozu Tacforiusa.
C/C, n. 4, Poligono Industrial Malpica ES-50016 Zaragoza Spain 
4, Poligono Industrial Malpica ES-50016 Zaragoza Španjolska
Tacforius reduces your body's defence mechanism (immune system), which will not be as good at fighting infections. 
Tacforius slabi obrambene mehanizme tijela (imunološki sustav), koji neće biti tako učinkovit u obrani od infekcija kao obično.
Tacforius should be administered in the morning. 
Tacforius je potrebno uzimati ujutro.
Certain combinations of tacrolimus with substances known to have nephrotoxic or neurotoxic effects may increase the risk of these effects (see section 4.5). 
Određene kombinacije takrolimusa i lijekova koje imaju nefrotoksične ili neurotoksične učinke mogu povisiti rizik od takvih učinaka (vidjeti dio 4.5).
Ostravská 29, č.p. 
Ostravská 29, c.p. 305
The use of Tacforius is not recommended in children and adolescents under 18 years. 
Ne preporučuje se primjena Tacforiusa u djece i adolescenata mlađih od 18 godina.
Tacforius therapy requires careful monitoring by adequately qualified and equipped personnel. 
Liječenje Tacforiusom mora biti pod strogim nadzorom odgovarajuće obučenih i opremljenih zdravstvenih radnika.
If signs of toxicity such as severe adverse reactions are noted (see section 4.8), the dose of Tacforius may need to be reduced. 
U slučaju da se primijete znakovi toksičnosti, kao što su teške nuspojave (vidjeti dio 4.8), možda će biti potrebno smanjiti dozu Tacforiusa.
From time to time, your doctor may need to do blood, urine, heart, eye tests, to set the right dose of Tacforius. 
Liječnik će Vam s vremena na vrijeme napraviti pretrage krvi, mokraće, srca i očiju, kako bi odredio pravu dozu Tacforiusa.
Significantly more ciclosporin-treated patients (n = 13) required a switch to tacrolimus than tacrolimus-treated patients to ciclosporin (n = 2) (p = 0.02) (Keenan et al., Ann Thoracic Surg 1995;60:580). 
Značajno više bolesnika liječenih ciklosporinom (n = 13) moralo je zamijeniti terapiju i prebaciti se na takrolimus, nego što se bolesnika liječenih takrolimusom moralo prebaciti na ciklosporin (n = 2) (p = 0,02) (Keenan et al., Ann Thoracic Surg 1995;60:580).
In cases of oral intoxication, gastric lavage and/or the use of adsorbents (such as activated charcoal) may be helpful, if used shortly after intake. 
U slučaju intoksikacije oralnim putem, ispiranje želuca i/ili primjena adsorbensa (poput aktivnog ugljena) mogu biti od pomoći ako se primijene ubrzo nakon uzimanja takrolimusa.